Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Palisade Bio (PALI) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Palisade Bio (PALI) over the last 14 years, with Q3 2025 value amounting to 58440.0%.

  • Palisade Bio's EBIT Margin changed N/A to 58440.0% in Q3 2025 from the same period last year, while for Sep 2025 it was 143212.5%, marking a year-over-year change of. This contributed to the annual value of 5228.0% for FY2023, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Palisade Bio's EBIT Margin is 58440.0%.
  • In the past 5 years, Palisade Bio's EBIT Margin ranged from a high of 231000.0% in Q1 2025 and a low of 1011.6% during Q1 2023
  • Moreover, its 3-year median value for EBIT Margin was 11600.0% (2021), whereas its average is 63901.3%.
  • Over the last 5 years, Palisade Bio's EBIT Margin had its largest YoY gain of 842400000bps in 2021, and its largest YoY loss of 331783900bps in 2021.
  • Quarter analysis of 3 years shows Palisade Bio's EBIT Margin stood at 11600.0% in 2021, then plummeted by -109bps to 1011.6% in 2023, then surged by 5877bps to 58440.0% in 2025.
  • Its EBIT Margin was 58440.0% in Q3 2025, compared to 142150.0% in Q2 2025 and 231000.0% in Q1 2025.